Novo Nordisk A/S (NONOF)
| Market Cap | 242.99B |
| Revenue (ttm) | 49.11B |
| Net Income (ttm) | 17.49B |
| Shares Out | n/a |
| EPS (ttm) | 3.93 |
| PE Ratio | 13.90 |
| Forward PE | 14.76 |
| Dividend | 1.66 (3.08%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 212,219 |
| Average Volume | 86,801 |
| Open | 56.51 |
| Previous Close | 55.51 |
| Day's Range | 53.86 - 56.51 |
| 52-Week Range | 45.00 - 139.99 |
| Beta | 0.32 |
| RSI | 43.59 |
| Earnings Date | Nov 5, 2025 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.
Financial numbers in DKK Financial StatementsNews
GLP-1 obesity pills face off in head-to-head trial
CNBC's Angelica Peebles joins 'Money Movers' to discuss Eli Lilly and Novo Nordisk battle over GLP-1 obesity pills.
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
GLP-1 obesity pills face off in head-to-head trial
CNBC's Angelica Peebles joins 'Money Movers' to discuss Eli Lilly and Novo Nordisk battle over GLP-1 obesity pills.
Warren Buffett Detailed Fundamental Analysis - NVO
Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor model based on the published strategy of ...
Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES , Sept. 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Novo Nordisk A/...
How Do Investors Really Feel About Novo Nordisk?
Novo Nordisk's (NYSE: NVO) short interest as a percent of float has risen 24.19% since its last report. According to exchange reported data, there are now 25.78 million shares sold short , which is 0...
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Novo To Contact Him Directly To Discuss Their Options
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2025...
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit – NVO
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action – NVO
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between May 7, 2025 and July 28, 2...
Novo Nordisk (NVO) Mandates Office Return Amid Major Restructuring
Novo Nordisk (NVO) Mandates Office Return Amid Major Restructuring
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming September 30, 2025 deadline to file a lead plaintiff motion in the class action filed on b...
Novo Nordisk directs employees to resume full-time office work
DEADLINE ALERT for SOC, LMT, NVO, and LINE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
LOS ANGELES, Sept. 11, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded...
Novo Nordisk tells staff to return to office full-time amid CEO's revival effort
Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries to accelerate decision-making and improve its commercial execution amid in...
September 30, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against NVO
NEW YORK , Sept. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
NOVO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm
The complaint alleges Novo overstated GLP-1 growth prospects; stock dropped 21.83% after lowered sales outlook citing compounded GLP-1 use and competition.
Novo Nordisk (NVO) Awaits Critical Alzheimer's Drug Trial Results
Novo Nordisk (NVO) Awaits Critical Alzheimer's Drug Trial Results
FIRST AID: VDL’s new global health plan
In today's edition: State of the Union, obesity, Novo Nordisk job cuts
Novo and Orsted Made Denmark Rich. Are The Boom Times Now Over?
At their heights, Denmark’s corporate champions seemed untouchable. Novo Nordisk A/S, long known mostly as an insulin maker, was Europe’s most valuable company last year, after riding a surge of deman...
Novo Nordisk slashes 9,000 jobs
Henrik Hallengreen Laustsen, senior analyst and equity research at Jyske Bank, joins BNN Bloomberg to discuss Novo Nordisk's bid to reignite growth.
Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up
Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to encroa...
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact The Gross Law Firm about pending Class Action - NVO
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Novo Nordisk A/S (NYSE: NVO).
Cigna cites flat obesity drug coverage rates among employers
Cigna (CI) reports flat employer coverage rates for obesity drugs like Wegovy from Novo Nordisk (NVO) and Zepbound from Eli Lilly (LLY). Read more here.
Ozempic maker to cut thousands of jobs
The Danish pharmaceutical company will reduce its 78,400-person workforce by approximately 9,000 positions to streamline operations and reinvest in diabetes and obesity drugs.